SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...
SAN DIEGO, June 15, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader in precision healthcare, announces the execution of an agreement with MultiPlan, a trusted partner to ...
The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...
SAN DIEGO, March 28, 2017 /PRNewswire/ -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique ...
PredictrPK IFX is now available for both the induction and maintenance phases of infliximab (IFX) therapy for inflammatory bowel disease (IBD) patients PredictrPK IFX addresses the unmet need of ...
Prometheus Laboratories' decision 10-plus years ago to patent a blood test that determines the maximum dose of a gastrointestinal drug is likely giving it major heartburn today. That's because the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results